© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
September 23, 2020
Investigators also reported that a subgroup of patients with 1 or more target kidney lesions experienced kidney tumor reduction and other benefits from the combination treatment.
September 16, 2020
The FDA has granted fast track designation to EPI-7386, an oral, highly selective N-terminal domain inhibitor of the androgen receptor for treatment of mCRPC resistant to standard-of-care treatment.
July 31, 2020
A multidisciplinary panel outlines criteria for stratifying risk for genitourinary malignancy in patients with microhematuria.
May 13, 2020
The FDA approved an additional recommended dosage of 400 mg every 6 weeks for the anti-PD-1 therapy pembrolizumab (Keytruda), across all adult indications, including monotherapy and combination therapy, Merck reported.